Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why BioCryst Pharmaceuticals Stock Slid Today

TheMotleyFool

0 0

Why BioCryst Pharmaceuticals Stock Slid TodayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png

BioCryst Pharmaceuticals (NASDAQ: BCRX) attracted the wrong kind of attention Wednesday with its latest quarterly results. By the end of the trading session, the stock had fallen by nearly 6%.

For the fourth quarter, BioCryst brought in net revenue of $47.2 million, nearly 12 times the $4.0 million it booked in the prior-year period. What made the difference was Orladeyo, a drug targeting hereditary angioedema (HAE) that was approved in December 2020. Orladeyo was responsible for $46.2 million of the company's net revenue last quarter.

Image source: Getty Images.

Source Fool.com

Like: 0

BCRX

Teilen